- 15 % en after
effectivement, ça a l'air tres séduisant ... merci jazmin
Je vais la suivre de près

VFCsStockHouse 7 mai 2012

Synergy Pharmaceuticals (SGYP): After flying higher over the past couple of months on the potential of the company's flagship product, Plecanatide for the treatment of chronic idiopathic constipation and constipation-predominant irritable bowel syndrome, positive reports by numerous analysts, and an FDA setback for a competing company, shares of Synergy Pharmaceuticals (SGYP) came back to earth late last week on the announcement of a stock offering that was priced at $4.50.

While the company took advantage of the recent price run to land a more favorable financing deal, the cash infusion may also strengthen Synergy's position as a potential buyout candidate as big players such as Pfizer (PFE) are flush with cash and possibly looking to make a few moves in order to boost pipelines depleted by popular drugs coming off patent.

Investors may see this pullback as another opportunity to take a chance on Plecanatide, which to this point has demonstrated a superior side effect profile than its potential competition. Additionally, Synergy should now have enough cash to carry through until the results are released from the ongoing Phase II/III trial, expected later this year.

Given the early-year runup and the pullback on the stock offering, Synergy remains a stock to watch.

celle là aussi, elle va casser la baraque à frites :D

Synergy Pharmaceuticals (SGYP): Volume is just now starting to return with strength to trading of Synergy Pharmaceuticals after a recent stock offering quickly returned shares to the $4.50 range from highs of over seven dollars reached shortly before the announcement. With significant catalysts pending for the remainder of the year relating to a drug that could have billion-dollar potential, this one may be ready to roll again.

Trial results for the company's lead product candidate, Plecanatide in the treatment of chronic idiopathic constipation (CIC) and constipation-predominant irritable bowel syndrome (IBS-C), are due later this year and provide the most notable pending catalyst, but there are other indicators and variables that could play a roll into a pre-announcement move higher.

Synergy's current market cap is just a fraction of that of its chief competitor, Ironwood Pharmaceuticals (IRWD). Thus far along in development, Plecanatide has proven to be at least as effective with none of the side effects presented by Ironwood's product, which is currently before the FDA for review. That fact alone would justify a higher market cap for Synergy, but add into the mix that Ironwood has already signed a deal to split proceeds of its product with Forest Laboratories, Inc. (FRX), and the case can be made that Synergy is highly undervalued in comparison.

With trial catalysts pending and a restocked war chest, SGYP is going to be a stock to watch for the coming weeks and months. When all things are considered, this could be one of the more undervalued plays out there right now in the sector, in terms of potential.

sur les bons coups

Elle tient bien le coup malgré claque des marchés today ...

Cela en dit long sur le potentiel de la pe tiote

Scott Matusow a écrit ce jour sur son compte Twitter :

"Been hearing buzz on $SGYP concerning large pharma partnership coming soon."

Il a semble-t-il des articles en préparation sur SGYP et AIS... laissons voir ce que ça donnera :

"I have several articles due out tomorrow; $SGYP, $AIS both on Seeking Alpha and biomedreports.com"

https://twitter.com/#!/ScottMatusow

Scott Matusow est classé N°1 sur seeking alpha dans la catégorie Healthcare :

http://seekingalpha.com/author/scott-matusow

voici son profile :

I have had the most success in trading/investing in smaller cap growth companies. I am not 'officially trained' in the markets, which allows me to see things 'outside the box.' I use my ability to read situations and emotion, combined with studying charts, times and sales, historical data, market forces along with macro economics and financial inner workings to predict stock price movements. Using these allowed for me to completely divest my own money and my family's money near the top of the market before the 2008 financial crisis.

cle

http://seekingalpha.com/article/634211-synergy-pharma-vying-for-a-piece-o f-the-20-billion-dollar-gastrointestinal-disorder-market

Synergy Pharma: Vying For A Piece Of The 20 Billion Dollar Gastrointestinal Disorder Market
June 4, 2012 | 1 comment | about: SGYP, includes: AIS, ARNA, IRWD, MRK
While attempting to find pharmaceutical companies that may take off in the short term, the buzz regarding one company I found was tough for me to ignore. I am always looking for small cap bio pharmas that have a shot at "Hitting the small cap bio pharma jackpot." I found one such company I think has a real shot at delivering the jackpot in the long term, which also has several nearer term catalysts that should provide some nice short term pps appreciation as well in my opinion.

Synergy Pharmaceuticals (SGYP) 6/1/12 pps: $4.54. Market cap: $291.95M

Synergy is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company's most developed product candidate is Plecanatide, which primarily treats chronic constipation (CC) and constipation-predominant-irritable bowel syndrome (IBS-C). The Company is also developing SP-333, its second generation GC-C receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis (UC). SP-333 is a synthetic analog of uroguanylin, a natriuretic hormone which is produced in the body's intestinal tract.

While reading about this company, I was very surprised to see how big the market is for gastrointestinal disorders. The estimates I see in the U.S. alone for prescriptions in this area are around $20 Billion, making it one of the largest therapeutic areas in the pharmaceutical industry.

At first I was wondering why this would be becoming such a huge industry. After reading more about these illnesses, it became clear that it is yet another area affected by the poor diets of Americans. This is why type two diabetes cases are skyrocketing. Along the same lines, weight loss pills are starting to become approved while giving some people "the easy way out." I went into this more in my article on Arena Pharmaceuticals (ARNA) and its drug Lorcaserin, which recently received a favorable 18-4 vote recommendation for approval from an FDA advisory panel.

I've discussed with many how I think it is terrible the way people are starting to rely on a pill to fix their body versus a proper diet and exercise. In my opinion, poor diets creating the need for more advanced GI medications is another sad reality, but a reality nonetheless. As generations of people become more obese and acquire increasingly poor diets then so too will the number of people suffering from these disorders rise.

With these facts in place, Synergy is swiftly acting on the opportunity to offer a medication that looks superior to anything in the market place in my opinion. In addition, they have some catalysts coming up that I find very attractive.

One of the catalysts coming up very quickly for Synergy is when they are added to the Russell 2000 index on June 22nd. One thing that this company has lacked because of just recently joining Nasdaq last year is institutional support. That is about to change as Synergy has qualified to become a part of this small cap market index. When the Russell rebalance occurs, funds are estimated to buy between 2-3M shares of SGYP.

Another company on the watch list of anyone with a major stake in Synergy is Ironwood Pharma (IRWD), who many would consider Synergy's biggest potential competitor. On September 9th, 2012, Ironwood will be looking for FDA approval on its competing drug Linaclotide, is also used to treat chronic constipation and irritable bowel syndrome. On April 23rd, 2012, Ironwood heard from the FDA that there would be a three-month delay regarding their New Drug Application (NDA). On the news of Ironwood's minor setback, Synergy popped to about $7 in less than a week.

With the lack of progress in this area filled with huge opportunities, there is no doubt room for both Ironwood and Synergy in the industry. In my opinion, the reason why we are seeing a lot of people taking notice of Synergy is that their trial results were better than Ironwood's for the same indications and they are trading at about 1/4th of the market cap. That was definitely the first thing that jumped out at me when looking at these two companies. Also, Synergy just joined the Nasdaq exchange last year and it can take time for the word to spread about a stock. Another reason Synergy is getting noticed may be the company's recent closing of its underwritten public offering of 10,000,000 shares of common stock at an offering price of $4.50 per share. Synergy received net proceeds, after deducting the underwriting discount and estimated offering expenses, of approximately $42.0 million. Synergy has also granted the underwriters a 45-day option to purchase up to an additional 1,500,000 shares of common stock to cover over-allotments, if any.

Synergy intends to use the net proceeds from this offering to fund its research and development activities, including its ongoing Phase II/III clinical trial of plecanatide and its Phase I clinical trial of SP-333, and for working capital and other general corporate purposes. My take on this offering is a bullish one; Synergy wants to ensure it gets its drug approved by the FDA, and it takes money to ensure all clinical data and manufacturing process are acceptable to the FDA. Many small cap companies fail to gain FDA approval for this reason; a lack of money. Synergy's management team is doing the right thing in my opinion to reach its goal. I think when facing a multibillion dollar market for its drug Plecanatide, the offering was definitely the prudent thing to do. Arena pharma just completed a stock offering at $5.50 a share to ensure its weight loss drug Lorcaserin not only gets approved (which in my opinion, is just about a given now), but that the company has the necessary working capital to correctly market Lorcaserin once it receives FDA approval. The Arena stock has appreciated nearly $1 since the offering.

Synergy has also been receiving a lot of analyst attention lately. Summer Street initiated coverage with a price target of $9, Brean Murray's rating was accompanied by a price tag of $13, and just a couple of weeks ago Roth Capital threw its own prediction into the mix with a target of $12. Plecanatide may have billion-dollar potential according to some analysts. Part of the reason for their attraction to Synergy may be found in a disturbing and recently published New York Times article that points to the over use of a laxative drug called Miralax, which is manufactured by Merck (MRK). Miralax generates about $200 million in annual sales revenue. Particually alarming from the NYT story is the Miralax has become a long-term solution for childhood constipation - a problem that can be troubling not just physically, but also emotionally.

The other hot rumor on our radar involves Synergy Pharmaceuticals (NASDAQ:SGYP).

As a fellow Seeking Alpha contributor points out, "trial results for the company's lead product candidate, Plecanatide [also known as SP304] in the treatment of chronic idiopathic constipation (CIC) and constipation-predominant irritable bowel syndrome (IBS-C), are due later this year and provide the most notable pending catalyst, but there are other indicators and variables that could play a roll into a pre-announcement move higher."

Industry sources tell us that Big Pharma may not even wait for those official results and could be ready to make a deal for SP304 shortly. Part of the reason for their attraction to the drug candidate may be found in a disturbing and recently published New York Times article that points to the over use of a laxative a drug called Miralax. The FDA approved that drug for use only by adults, and for only seven days at a time, yet Miralax has become a long-term solution for childhood constipation. The article points out that while no studies have shown that the drug's active ingredient (polyethylene glycol 3350) has severe side effects, there is a growing chorus of questions about why parents and doctors have used and prescribed it for children for so many years.

In a statement, Merck (MRK) said that it recommends the use of Miralax only for patients 17 and older and only for a week, and added that it "regularly analyzes and reports all adverse event information as part of our ongoing post-marketing surveillance."

Those of you familiar with Synergy know that the company is focused primarily on the development of drugs to treat gastrointestinal disorders and diseases.

Synergy Pharmaceuticals' product, SP-304 is a synthetic analog of uroguanylin, a natural gastro-intestinal hormone that is produced in the gastro-intestinal (GI) tract and is a key regulator of intestinal function.

SP304/ Plecanatide devwis in Phase III for Constipation (Chronic Idiopathic Constipation). It is in Phase I for Irritable Bowel Syndrome (Constipation-Predominant Irritable Bowel Syndrome) and was previously discontinued as therapeutic indication for both Colon Cancer and Inflammatory Bowel Disease

The receptor, called the guanylate cyclase C (GC-C) receptor, promotes fluid and ion transport in the GI tract. Under normal conditions, the receptor is activated by the natural hormones uroguanylin and guanylin. Activation of the receptor leads to the transport of chloride and bicarbonate into the intestine.

Among the seven milestones listed for Synergy in the BioMedReports FDA Calendar, one indicates that Synergy anticipates completing enrollment of the Plecanatide Phase II/III trial in the third quarter of 2012 and reporting top line data in the fourth quarter 2012.

If you're considering a bet here, from a risk reward perspective, we like the fact that the company recently completed a big financing in which Synergy received net proceeds of approximately $42.0 million. Our readers would be coming in post that dilution and share prices could start to wake up after a period of consolidation at these levels if the leaks about the possible pharma deal continue to spread.

(click to enlarge)

5.365.000 titres traités en after et quasi tout à l'achat sauf 44 410 pauvres titres en vente

un ordre à 22h00.01 de 10.4 mio de $ !!! pour un peu plus de 2mio de titres à 4.91

et puis après encore pour plus de 3mio de titres à l'achat

total +- 9.5% du capital échangé mais à contrario de imuc où il y avait en after +- 2mio à l'achat et 2mio à la vente ; ici c'est plus de 5mio à l'achat

curieux de la voir lundi

bon week-end à tous

Vincent

Hello Vince !

Comment est il possible d'effectuer des achats avec de tels volumes sans faire bouger le prix de l'action ou de si peu ?

Salut,
Et on remarque de gros achats en fin de séance sur beaucoup de biotechs sans variation de cours.
Si quelqu'un à une explication....

Russell rebalancing

http://bit.ly/kuJWHX

mais je compte pas en rester là

je la suivais de près depuis les 4,40
maintenant c'est bon
par contre, plus de news de jazmin (daniele)
je vais partir prendre des nouvelles

Toujours IN, Sacha, avec 1000 actions.. Mais je l'ai malheureusement achetée à 5,41, juste avant l'AK.
Elle se refait une santé petit à petit. Ma MV n'est plus que de -6,27% contre -44% il y a peu!

2 articles pr s'n convaincre :

1/ VFC Stock House

Synergy Pharmaceuticals: A Buying Opportunity Now That Could Pay Off Nicely Later

Posted by Posted by VFC on Aug 06, 2012

Shares of Synergy Pharmaceuticals (SGYP) have slipped over the past couple of weeks and are again trading at levels under the four dollar mark, prices not seen in many months beforehand. With key catalysts pending for this company later in the year and with a product in the late stages of development that could be worth billions over the long run on the open market, SGYP could be trading for quite the relative bargain at the current time. As the year progresses and the significant trial catalyst draws nearer, Synergy could be gearing up for a reversal from the current downtrend.

Also encouraging, Synergy secured a key merger agreement last month with Callisto Pharmaceuticals (CLSP) that wholly boosts the company's short and long term potential. For months investors had been wondering when the SGYP market cap would begin to approach that of competitor Ironwood Pharmaceuticals (IRWD), which sits at well over a billion dollars, since Synergy's Plecanatide has proven thus far in studies to have a superior side effect profile to Ironwood's Linaclotide, which is currently before the FDA for approval review.

The Callisto/Synergy merger opens the door for an equalization in market cap.

Previous to the merger, Callisto had owned roughly forty percent of SGYP shares. Such a heavy investment by one entity often keeps large funds and new heavy investors from taking a stake in a company that is ultimately largely controlled by another entity. That will no longer be the case since the merger spreads Callisto's Synergy holdings throughout the entire Callisto shareholder base, therefore eliminating the forty percent control by one entity. As previously discussed, that opens the door for large funds and institutions to start buying in.

Also of significant note, the SGYP shares being spread across the Callisto shareholder base will be 'locked up' for eighteen months - unless a "Change of Control" even takes place first - which means the shares will not weigh down the SGYP share price in the meantime. The "Change of Control" language also raises the already robust buyout speculation surrounding the company, as the Synergy management team may be already looking for suitors. To speculate further, Synergy may have already been advised that the Callisto holdings may be the roadblock to completing such a deal, hence the need for the merger.

The completion of this merger strengthens the case of SGYP as both a short and long term investment. IRWD's Linaclotide is already before the FDA for approval in the treatment of chronic idiopathic constipation (CIC) and could receive the nod next month - barring any additional decision delays - and such an approval would validate the technology and could also provide a boost to SGYP.

Plecanatide, however, has already proven in trials to have a favorable side-effects profile than Linaclotide, hence the belief that the product could quickly steal market share, once approved. Data from the pending Phase II/III trial later this year are widely expected to roll in positive, based on previous studies, as well as the noted success of Linaclotide, which shares origins and the same mechanism of action with Plecanatide.

Both Linaclotied, and Synergy's competing product Plecanatide, are also being developed to treat constipation-predominant irritable bowel syndrome (IBS-C).
Another positive for Synergy is that the company is still yet to land a major partner or buyer, while Ironwood has already partnered its product with Forest Laboratories, Inc. (FRX). Since IRWD's market cap already sits well north of a billion dollars, the market is valuing Linaclotide at roughly double that, since IRWD is only due to receive a royalty of fifty percent of future sales.

Those facts alone justify the belief that SGYP could start inching towards a much higher valuation with the Callisto deal finalized - especially if the trial results later this year are as positive as they have been previously.

Given the recent developments, pending catalysts and share price retreat, SGYP is one to keep an eye on right now. In just a few months time, it's possible that the current prices will be looked back upon as a bargain.

Disclosure: Long SGYP.

2/Seeking Alpha

Weekly Stock Watch, Week Of August 6
August 5, 2012

Synergy Pharmaceuticals (SGYP): Synergy Pharmaceuticals is yet another company in the biotech/small pharma sector that has seen its share price sink to once-again very attractive levels. This company has numerous key catalysts pending that could quickly reverse the retreating trend, namely the release of decisive trial results later this year that would give reason to believe that the SGYP market cap could quickly approach that of competitor Ironwood Pharmaceuticals (IRWD), which sits at well over a billion dollars.

Ironwood's product, Linaclotide, is already before the FDA for approval in the treatment of chronic idiopathic constipation (CIC) and could receive the nod next month, barring any additional decision delays. Both Linaclotied, and Synergy's competing product Plecanatide, are also being developed to treat constipation-predominant irritable bowel syndrome (IBS-C).

Plecanatide, however, has already proven in trials to have a favorable side-effects profile than Linaclotide, hence the belief that the product could quickly steal market share, once approved. Data from the pending Phase II/III trial later this year are widely expected to roll in positive, based on previous studies, as well as the noted success of Linaclotide, which shares origins and the same mechanism of action with Plecanatide.

Synergy also has the pending potential of landing a major partner or buyer.

Ironwood has already partnered its product with Forest Laboratories, Inc. (FRX), which makes the company's market cap of already well over a billion dollars roughly half of what the market is valuing Linaclotide, since IRWD is only due to receive a royalty of fifty percent of sales.

Assuming Plecanatide's superior side effect profile and the potential of the product to quickly eat away at IRWD's market share, it's conceivable that SGYP should soon start looking to at least match the cap of Ironwood. One impediment to making that happen was the fact that Callisto Pharmaceuticals (CLSP) had owned roughly forty percent of SGYP shares. Such a heavy investment by one entity often keeps large funds and new heavy investors from taking a stake in a company that is ultimately largely controlled by another entity. That will no longer be the case since Callisto and Synergy recently announced a merger that would spread Callisto's Synergy holdings through the entire Callisto shareholder base, therefore eliminating the forty percent control by one entity.

This scenario strengthens the case for SGYP to start being looked at as an attractive investment option for investors of all sizes, especially considering the pending catalysts. Also of significant note, the SGYP shares being spread across the Callisto shareholder base will be 'locked up' for eighteen months - unless a "Change of Control" even takes place first - which means the shares will not weigh down the SGYP share price in the meantime.

The "Change of Control" language also raises the already robust buyout speculation surrounding the company, as the Synergy management team may be already looking for suitors. To speculate further, Synergy may have already been advised that the Callisto holdings may be the roadblock to completing such a deal, hence the need for the merger.

Should a buyout become the endgame, don't expect that before the trial results of later this year. If those results come in as encouraging as expected, then it could be, as they say, "all bets are off" and the bidding will begin.

Worth keeping an eye on this one, and also worth taking advantage of the share price dip, in my opinion.

En tous les cas, on en parle beaucoup ces derniers jours. Toujours IN.
Article du 7 août.

Synergy Pharmaceuticals: A Buying Opportunity Now That Could Pay Off Nicely Later
by VFC's Stock House

While the inherent nature of trading in the biotech/healthcare sector is always risky and there are far more stories of failure than success as many drugs fail to make it through late stage trials, proper DD and investigation into developments at Synergy Pharmaceuticals (SGYP) could reveal an attractive buying opportunity for those willing to play the volatile nature of the sector. read more »

More on SGYP:
Synergy Pharmaceuticals Strengthened By Merger Agreement by VFC's Stock House
Keep Synergy On Your Radar As Stocks Inch Higher by VFC's Stock House
Synergy Pharma's Potential Widens As Volume Picks Up by VFC's Stock House

Other articles that mention SGYP:
Weekly Stock Watch, Week Of August 6 by VFC's Stock House
Weekly Stock Watch: Week Of July 30 by VFC's Stock House
Russell 3000 U.S. Healthcare Additions For June 2012 by EXPstocktrader

si le cours retombe sur 3,50$ je rajouterai qques cartouches..

>CB : 245 Mlns $
>Cash : 43.5 Mlns $ (Au 30.06) ; ça laisse théoriquement 2 ans d'autonomie (cash burn de 23,8 mlns $ sur les 4 derniers trimestres) - en tous cas ça paraît suffisant pr aller jusqu'au Q4

>Les analystes optimistes:

Summer Street a un objectif de 9 $,
Brean Murray vise un cours de 13$,
Roth Capital anticipe un cours de 12$...

>J’ai un objectif de cours de 10$ sur le titre avant la fin de l’année si un partenariat est signé et que les données sur Plecanatide sont positives

tte mauvaise nouvelle sur IRWD (qui va passer devant la FDA le mois prochain pr un pdt similaire à celui de SGYP) sera bénéfique

le pblème avec IRWD ce sont les effets secondaires (diarrhées 'extrêmes') si bien que 6% des patients ont du arrêter le traitement alors que le Plecanatide de SGYP n'a pas jusqu'alors démontré de tels effets 2ndaires

le potentiel de ventes est quand même de 2 mlds $..

Le courtier AEGIS balance un Obj de 25$ today

La note ici :

http://bit.ly/SiQ8uv

"Synergy's current market cap of about $250mm does not adequately value the potential of Plecanatide and the firm's platform technology, in our view. We also note that linaclotide is currently valued at a level approaching $3bn based on the market cap of Ironwood Pharmaceuticals (IRWD/NASDAQ - Buy), the originator of this agent."

ma plus grosse ligne en biotech

Même un objectif sur les 6 me convient

Allez la bise au passage

résultats plecanatide, svp

En vous remerciant

SGYP est devenu ma conviction pour le reste de l’année.. je profiterai de toute baisse de titre pour renforcer

pour toi kantt :


>confirmation : résu Fin-2012

ça a été confirmé le 13/08 lors de l'annonce de la fin du recrutement des 880 patients: résu Phase IIb/III plecanatide prévus pour fin 2012

"Synergy anticipates topline data being released by year
end."

http://www.noodls.com/view/BCF38DFA18C4D7F1559F7041D6A2A7F929A0A01 2

SGYP un bon Ticket pour fin-2012. précisions :

1-soumission NDA fin 2012?

D'après les analystes, l'appro du Pleca serait prévu pour 2015 .. mais une demande de NDA pourrait être déposée dès la fin de l'annèe si les résu sont bons (tt dépendra du critère principal). ça signifierait entre 1 et 1 an et demi de mieux que le calednrier initial. Le risque ce serait de conduir un essai supplèmentaire, mais de ttes façons c'est ce qui est dèjà pricé..


2- management

Une info intéressante : le management est très expérimenté

Le Président du Conseil d'administration est un certain Gabriele Cerrone (depuis 2008) - voir sur leur site

Pr information, Mr Cerrone était le plus gros actionnaire d' INHX lorsque la scté a été vendue l'an passé à BMS pour 2,5 Mlds $..

Tout le reste du managmenet présente un CV à rallonge ; ils ont tous une solide expérience ou un PhD .. et puis ils partagent des "valeurs" (voir la partie values sur leur site, une partie qu'on a pas trop l'habitude de voir sur des bio)

3-SGYP vs IRWD

Je rappelle quand même que la diff de Valo. entre SGYP et IRWD est de 1 mds $ POUR LA MEME INDICATION tout en sachant que SGYP a demeilleurs résultats notamment sur les épisodes associés aux dia r.rh ées. Ensuite, difficil de savoir ce qu'il se passera pr IRWD en septembre sur son appro FDA.. masi s'ils font fausse route alors je vous dis pas le Up de folie de SGYP

4-Partenariat

Enfin, l'autre chose importante c'est qu'aucun partenariat n'a encore été annoncé hey hey!

Si elle y retourne ...

Partons du scénario que la FDA donne son feu vert pour IRWD en Septembre ... risque de contagion à la hausse sur SGYP possible ...

Et si refus ... là on connaît l'érection probable

du FV-100 à BMS

1 pilule / jour contre 12 pilules pour le Valtrex de GSK (339 Mlns de £ de ventes en 2011).

FV-100

du FV-100 à BMS qui a terminé le recrutement de phase 2a

1 pilule / jour pour le FV100 contre 12 pilules / jour avec Valtrex de GSK (Valtrex a réalisé 339Millions de pounds de ventes en 2011)

La bonne news c'est que cette acquisition ne coute que 1 millions $;

Alors ce qu'il y a d'intèressant aussi, c'est que SGYP a racheté les droits à BMS qui avait récupéré ce traitement lors du rachat de INHX.. et comme je l'avais spécifié plus haut, le pdt du conseil d'administration de SGYP est un ancien de INHX

et apres c'est le nirvanahahahaha !!

depuis mon renfort @ 3.79 c'est devenu ma plus grosse ligne (12 titres biotechs en portefeuille en ce moment).

un titre qui promet et que je ne suis pas prêt de brader !

Avec 3000 titres, c'est aussi ma plus grosse ligne. Bien remontée car PRU a 4,90$ à présent.Fichue AK!
ON Y CROIT!

http://seekingalpha.com/article/838611-simple-math-showing-why-synergy-pharmaceu ticals-is-undervalued?source=kizur

Lire cet article est intetessant:



http://mobile.businessweek.com/news/2012-08-30/ironwood-forest-irritable-bowel-t herapy-wins-fda-approval

Ca ne parle pae pas de SGYP
Mais vous allez comprendre pkoi SGYP pourrait dechirer le calbute de IRWD (IRWD ne traite pas les symptomes mais calme la douleur).. Et pr moi c'est là ou SGYP pourra torcher IRWD

j'ai peur qu'elle retourne sur les 4,50 (MM 50 et retracement 23,6 % de Fibo)

aujourd'hui malgrè le bon comportement des indices (+3% à Paris ; +1,6% à NY) SGYP perd -3,00% dans de faibles volumes

c'est une société qui me paraît clairement avoir le potentiel d'aller taper les 6$ dans un premier temps - je parle même pas de partenariat, là ça serait EXPLOSION divERGENTE pas vrai chinchin ;-)

mais la voir buter sur les 5$ ça me rassure pas trop.. surtout si les indices se mettent à planter maintenant que la News est venue de la BCE, que Jackson Hole est passé et que la prochaine date très importante (macro) semble être le 12 Septembre ; bref pour une fois j'ai peur d'avoir les mains tremblantes sur une pépite

SGYP est à part. Elle est capable de booster n'importe quand.

initiée mi-août. Si ça casse, y a effectivement de grandes chances qu'elle retourne sur 4.5

Difficile de la comprendre cette garce ... D autant plus quant cola tombe en maintenant qu une nouvelle plutot positive

Reste plus qu à attendre me concernant car je Reste aveuglement convaincu qu elle va exploser ...

Bonen aprem

Kanttt

Source: Synergy Pharmaceuticals
Date: September 12, 2012 08:39 ET
Synergy Pharmaceuticals Files IND for SP-333, a Developmental Drug for Gastrointestinal Diseases
NEW YORK, Sept. 12, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that an Investigational New Drug (IND) application was submitted on September 7, 2012 for clinical evaluation of SP-333 to treat inflammatory bowel disease (IBD). SP-333 is a second-generation guanylate cyclase-C (GC-C) agonist with the potential to treat GI disorders and diseases.

"SP-333, to our knowledge, represents the most potent and stable uroguanylin analog ever developed," stated Dr. Gary S. Jacob, President and CEO of Synergy Pharmaceuticals. "The submission of the IND on SP-333 is a major milestone for the company, as it broadens our clinical portfolio of GC-C agonists for treatment of GI disorders and diseases."

"The science behind SP-333 marks a new approach to the treatment of GI inflammatory diseases," said Dr. Kunwar Shailubhai, Chief Scientific Officer of Synergy Pharmaceuticals. "We are excited with SP-333's impressive anti-inflammatory activity. In studies with experimental models of colitis in mice, SP-333 at an oral dose as low as 0.05 mg/kg body weight demonstrated superior anti-inflammatory activity compared to 5-aminosalicylic acid (5-ASA) given at a dose of 100 mg/kg."

About SP-333

SP-333 is a synthetic analog of uroguanylin, a natriuretic hormone which is normally produced in the body's intestinal tract. Deficiency of uroguanylin is likely to be one of the primary reasons associated with formation of polyps as well as debilitating and difficult-to-treat GI inflammatory disorders such as ulcerative colitis and Crohn's disease. Orally-administered SP-333 binds to and activates guanylate cyclase C (GC-C) expressed on epithelial cells lining the GI mucosa, resulting in stimulation of cyclic GMP in target tissues. SP-333 has been found to be highly stable against proteolysis in simulated intestinal fluid for up to 24 hours. Its enhanced stability makes this peptide an extremely potent GC-C agonist in animal studies in mice and monkeys, promoting bowel movement in monkeys, and ameliorating GI inflammation in mice, respectively.

About Synergy Pharmaceuticals Inc.

Synergy is a biopharmaceutical company focused on the development of new drugs to treat gastrointestinal disorders and diseases. Synergy's lead proprietary drug candidate plecanatide is a synthetic analog of the human gastrointestinal hormone uroguanylin, and functions by activating the guanylate cyclase C receptor on epithelial cells of the GI tract. Synergy completed a Phase I study of plecanatide in healthy volunteers and a Phase IIa clinical trial in CIC patients. In October, 2011, Synergy initiated dosing of patients in a major Phase II/III clinical trial of plecanatide to treat chronic idiopathic constipation. Plecanatide is also being developed to treat constipation-predominant irritable bowel syndrome, with the first trial in IBS-C patients planned for the second half of 2012. Synergy's second GC-C agonist SP-333 is currently in pre-clinical development to treat inflammatory bowel diseases. More information is available at http://www.synergypharma.com.

About Plecanatide

Plecanatide is a member of a new class of essentially non-systemic drugs, referred to as guanylate cyclase C (GC-C) agonists, which are currently in development to treat CIC and IBS-C. Plecanatide is a synthetic analog of uroguanylin, a natriuretic hormone that regulates ion and fluid transport in the GI tract. Orally-administered plecanatide binds to and activates GC-C receptors expressed on epithelial cells lining the GI mucosa, resulting in activation of the cystic fibrosis transmembrane conductance regulator (CFTR), and leading to augmented flow of chloride and water into the lumen of the gut. Activation of the GC-C receptor pathway is believed to facilitate bowel movement as well as producing other beneficial physiological responses including improvement in abdominal pain and inflammation. In animal models, oral administration of plecanatide promotes intestinal secretion and also ameliorates GI inflammation.

Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "planned," "believe," "forecast,""estimated," "expected," and "intend," among others. These forward-looking statements are based on Synergy's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Synergy's Form 10-K for the year ended December 31, 2011 and other periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Synergy does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.

CONTACT: Investor Contact Information:

Danielle Spangler
The Trout Group
synergy@troutgroup.com
(646) 378-2924